1. Scrip
  2. >>Business
  3. >>Strategy

Bayer Boss Rules Out Divisions Split For Now

 
• By Kevin Grogan

CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”

pill
• Source: Bayer

Investors who have been pushing for Bayer AG to break its three-pillar structure of pharmaceuticals, consumer health and crop science will have to wait for a couple more years at least, as CEO Bill Anderson tells journalists that the firm's pipeline, debt, legal and bureaucracy problems need fixing first.

Speaking at the German group's annual results conference in London, Anderson noted that Bayer had "seriously considered the structure of our company [with] the help of numerous external advisors and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.